DCOL Center for Clinical Research | Longview, TX

Research site

(Unclaimed)

Location

707 Hollybrook Drive, Suite 501, Longview, Texas, United States of America

Site insights

Top conditions

Top treatments

Emtricitabine

TDF

Tenofovir Alafenamide

TAF

Rilpivirine

Tenofovir Disoproxil Fumarate

Lubiprostone

Efavirenz

Lenacapavir

Ritonavir

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 67 total trials

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382

Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic di...

Enrolling

Human Immuno-deficiency Virus (HIV) Disease

Drug: Budigalimab

Drug: ABBV-382

Locations recently updated

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of do...

Enrolling

HIV-1 Infection

Drug: BIC/FTC/TAF

Drug: Placebo to DOR/ISL

Dose Ranging, Switch Study of Islatravir (ISL) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

This is a randomized, controlled, double-blind, study to evaluate the safety and tolerability of islatravir (ISL) + ulonivirine based on review of th...

Active, not recruiting

HIV-1 Infection

Drug: Islatravir

Drug: Placebo to Ulonivirine

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation (NOTUS)

Primary Objective:To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary...

Active, not recruiting

Chronic Obstructive Pulmonary Disease

Drug: Placebo

Drug: Inhaled Long-Acting Muscarinic Antagonist

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (CAPELLA)

The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing re...

Active, not recruiting

HIV-1-infection

Drug: Optimized Background Regimen (OBR)

Drug: Oral Lenacapavir Placebo